Mineralocorticoid Receptor Antagonists—Use in Chronic Kidney Disease
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Mineralocorticoid Receptor Antagonists—Use in Chronic Kidney Disease
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 22, Issue 18, Pages 9995
Publisher
MDPI AG
Online
2021-09-17
DOI
10.3390/ijms22189995
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Disease characteristics and outcomes in patients with chronic kidney disease and type 2 diabetes: a matched cohort study of spironolactone users and non-users
- (2020) Michael Blankenburg et al. BMC Nephrology
- Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial
- (2020) Nete Tofte et al. Lancet Diabetes & Endocrinology
- Baseline urinary metabolites predict albuminuria response to spironolactone in type 2 diabetes
- (2020) Skander Mulder et al. Translational Research
- Apararenone in patients with diabetic nephropathy: results of a randomized, double-blind, placebo-controlled phase 2 dose–response study and open-label extension study
- (2020) Takashi Wada et al. Clinical and Experimental Nephrology
- Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine
- (2020) Rajiv Agarwal et al. EUROPEAN HEART JOURNAL
- Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
- (2020) George L. Bakris et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mineralocorticoid receptor antagonists in patients with chronic kidney disease
- (2020) Cosimo Cosimato et al. PHARMACOLOGY & THERAPEUTICS
- The effect of aldosterone and aldosterone blockade on the progression of chronic kidney disease: a randomized placebo-controlled clinical trial
- (2020) Hitoshi Minakuchi et al. Scientific Reports
- Finerenone and Cardiovascular Outcomes in Patients with Chronic Kidney Disease and Type 2 Diabetes
- (2020) Gerasimos Filippatos et al. CIRCULATION
- Esaxerenone (CS-3150) in Patients with Type 2 Diabetes and Microalbuminuria (ESAX-DN)
- (2020) Sadayoshi Ito et al. Clinical Journal of the American Society of Nephrology
- Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis
- (2019) Jonatan Barrera-Chimal et al. KIDNEY INTERNATIONAL
- Renal function stratified dose comparisons of eplerenone versus placebo in the EMPHASIS‐HF trial
- (2019) João Pedro Ferreira et al. EUROPEAN JOURNAL OF HEART FAILURE
- A randomized controlled trial of the effect of spironolactone on left ventricular mass in hemodialysis patients
- (2019) Fabian Hammer et al. KIDNEY INTERNATIONAL
- Patient characteristics and initiation of mineralocorticoid receptor antagonists in patients with chronic kidney disease in routine clinical practice in the US: a retrospective cohort study
- (2019) Michael Blankenburg et al. BMC Nephrology
- Efficacy and safety of dosage-escalation of low-dosage esaxerenone added to a RAS inhibitor in hypertensive patients with type 2 diabetes and albuminuria: a single-arm, open-label study
- (2019) Hiroshi Itoh et al. HYPERTENSION RESEARCH
- Effects of mineralocorticoid receptor antagonists in proteinuric kidney disease
- (2019) Maria-Eleni Alexandrou et al. JOURNAL OF HYPERTENSION
- Effect of Patiromer on Hyperkalemia Recurrence in Older Chronic Kidney Disease Patients Taking RAAS Inhibitors
- (2018) Matthew R. Weir et al. AMERICAN JOURNAL OF MEDICINE
- The tolerability and safety profile of patiromer: a novel polymer-based potassium binder for the treatment of hyperkalemia
- (2018) Bertram Pitt et al. Expert Opinion On Drug Safety
- Safety and cardiovascular efficacy of spironolactone in dialysis-dependent ESRD (SPin-D): a randomized, placebo-controlled, multiple dosage trial
- (2018) David M. Charytan et al. KIDNEY INTERNATIONAL
- Long-Term Effects of Spironolactone on Kidney Function and Hyperkalemia-Associated Hospitalization in Patients with Chronic Kidney Disease
- (2018) Chen-Ta Yang et al. Journal of Clinical Medicine
- Predicting albuminuria response to spironolactone treatment with urinary proteomics in patients with type 2 diabetes and hypertension
- (2017) Morten Lindhardt et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- The Safety and Efficacy of Mineralocorticoid Receptor Antagonists in Patients Who Require Dialysis: A Systematic Review and Meta-analysis
- (2016) Kevin Quach et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis
- (2016) Gemma Currie et al. BMC Nephrology
- Anti-albuminuric effects of spironolactone in patients with type 2 diabetic nephropathy: a multicenter, randomized clinical trial
- (2015) Sawako Kato et al. Clinical and Experimental Nephrology
- The Safety of Eplerenone in Hemodialysis Patients: A Noninferiority Randomized Controlled Trial
- (2015) M. Walsh et al. Clinical Journal of the American Society of Nephrology
- Safety profile of mineralocorticoid receptor antagonists: Spironolactone and eplerenone
- (2015) Mitja Lainscak et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy
- (2015) George L. Bakris et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Long-Term Effects of Low-Dose Spironolactone on Chronic Dialysis Patients: A Randomized Placebo-Controlled Study
- (2015) ChongTing Lin et al. Journal of Clinical Hypertension
- Beneficial long-term effect of aldosterone antagonist added to a traditional blockade of the renin–angiotensin–aldosterone system among patients with obesity and proteinuria
- (2015) Enrique Morales et al. NEFROLOGIA
- Patiromer in Patients with Kidney Disease and Hyperkalemia Receiving RAAS Inhibitors
- (2015) Matthew R. Weir et al. NEW ENGLAND JOURNAL OF MEDICINE
- Diabetic Kidney Disease: A Report From an ADA Consensus Conference
- (2014) Katherine R. Tuttle et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Incidence, Predictors, and Outcomes Related to Hypo- and Hyperkalemia in Patients With Severe Heart Failure Treated With a Mineralocorticoid Receptor Antagonist
- (2014) Orly Vardeny et al. Circulation-Heart Failure
- Drug-Induced Hyperkalemia
- (2014) Chaker Ben Salem et al. DRUG SAFETY
- Finerenone, a Novel Selective Nonsteroidal Mineralocorticoid Receptor Antagonist Protects From Rat Cardiorenal Injury
- (2014) Peter Kolkhof et al. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
- Safety and Efficacy of Eplerenone in Patients at High Risk for Hyperkalemia and/or Worsening Renal Function
- (2013) Romain Eschalier et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Evaluation of spironolactone plus hydrochlorothiazide in reducing proteinuria in type 2 diabetic nephropathy
- (2013) Ali Momeni et al. JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM
- Long-term effects of addition of mineralocorticoid receptor antagonist to angiotensin II receptor blocker in patients with diabetic nephropathy: a randomized clinical trial
- (2013) A. Esteghamati et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Rationale and design of the Mineralocorticoid Receptor Antagonists in End-Stage Renal Disease Study (MiREnDa)
- (2013) F. Hammer et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Effect of spironolactone combined with angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers on chronic glomerular disease
- (2013) WEISONG WANG et al. Experimental and Therapeutic Medicine
- Management of hyperkalaemia consequent to mineralocorticoid-receptor antagonist therapy
- (2012) Sara S. Roscioni et al. Nature Reviews Nephrology
- Change in Proteinuria After Adding Aldosterone Blockers to ACE Inhibitors or Angiotensin Receptor Blockers in CKD: A Systematic Review
- (2008) Andrew S. Bomback et al. AMERICAN JOURNAL OF KIDNEY DISEASES
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now